View Post

‘Striking’ Responses in Pediatric Solid Tumors With Entrectinib

In Clinical Trials by Barbara Jacoby

By: Nick Mulcahy From: medscape.com The investigational oral therapy entrectinib (Genentech/Roche) produced “striking, rapid, and durable” objective responses in children with recurrent/refractory central nervous system (CNS) and solid tumors harboring a range of target gene fusions, said Giles Robinson, MD, pediatric neuro-oncologist, St Jude Children’s Research Hospital, Memphis, Tennessee. The median age of these patients was 7 years old. Robinson …

View Post

US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment

In Clinical Trials by Barbara Jacoby

Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts. A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland, speeding the process of patient recruitment and data collection. The company, Moleculin (NASDAQ: MBRX), recently recruited 3 patients in 6 …

View Post

Alisertib-Based Combo Improves Survival Outcomes in Ovarian, Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Skarzynski From: curetoday.com For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated promising activity in patients with recurrent ovarian cancer or advanced breast cancer. In the JAMA Oncology study, the …

View Post

Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications

In Clinical Trials by Barbara Jacoby

From: ptcommunity.com Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today announced that it has dosed the first patient in its Phase 1/2 clinical trial of EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate being developed for the treatment of …

View Post

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

In Clinical Trials by Barbara Jacoby

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a novel, versatile, multi-functional platform- -Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favorable safety profile in early stage cervical cancer- -Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 …